ArticleJournal of Alzheimer's disease : JAD2021
Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study.
Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of hippocampal volumetry in Alzheimer's disease or mild cognitive impairment: a meta-analysis.European radiology · 2022Pooled it
- Association between automated brain volumetry and visual classification of hippocampal atrophy in MRI.Neuroimage. Reports · 2026Article
- Magnetic Resonance Imaging-Based Cortical and Subcortical Volumetric Changes in Alzheimer's Disease: Association with Clinical Severity.Diagnostics (Basel, Switzerland) · 2026Article
- Biomarker-Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease-Modifying Treatments: A Consensus Statement by Belgian Experts.European journal of neurology · 2026Article
- Agentic AI for scaling diagnosis and care in neurodegenerative disease.Nature aging · 2026Review
- Comparative Analysis of Four Commercially Available Artificial Intelligence Software for Brain Volumetry.Diagnostics (Basel, Switzerland) · 2026Article
- A computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans.Journal of Alzheimer's disease : JAD · 2025Article
- Real-world brain imaging in a population-based cohort enables accurate markers for dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Implementing early detection of cognitive impairment in primary care to improve care for older adults.Journal of internal medicine · 2025Review
- Independent validation and outlier analysis of EuroPOND alzheimer's disease staging model using ADNI and real-world clinical data.Alzheimer's research & therapy · 2025Article
- AI-based staging, causal hypothesis and progression of subjects at risk of Alzheimer's disease: a multicenter study.Frontiers in neurology · 2025Article
- Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.Journal of neurology · 2024Article
- Automated Volumetric Software in Dementia: Help or Hindrance to the Neuroradiologist?AJNR. American journal of neuroradiology · 2024Article
- Brain age as a biomarker for pathological versus healthy ageing - a REMEMBER study.Alzheimer's research & therapy · 2024Article
- Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease.ACS chemical neuroscience · 2024Article
- Automated brain segmentation and volumetry in dementia diagnostics: a narrative review with emphasis on FreeSurfer.Frontiers in aging neuroscience · 2024Review
- Response to the 'Letter to the editor'-10.1007/s00234-022-02906-z.Neuroradiology · 2022Article
- Investigating Tissue-Specific Abnormalities in Alzheimer's Disease with Multi-Shell Diffusion MRI.Journal of Alzheimer's disease : JAD · 2022Article
- Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls.Frontiers in aging neuroscience · 2021Article
- Recent contributions to the field of subjective cognitive decline in aging: A literature review.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMagnetic resonance imaging (MRI) has become important in the diagnostic work-up of neurodegenerative diseases. icobrain dm, a CE-labeled and FDA-cleared automated brain volumetry software, has shown potential in differentiating cognitively healthy controls (HC) from Alzheimer's disease (AD) dementia (ADD) patients in selected research cohorts.
objectiveThis study examines the diagnostic value of icobrain dm for AD in routine clinical practice, including a comparison to the widely used FreeSurfer software, and investigates if combined brain volumes contribute to establish an AD diagnosis.
methodsThe study population included HC (n = 90), subjective cognitive decline (SCD, n = 93), mild cognitive impairment (MCI, n = 357), and ADD (n = 280) patients. Through automated volumetric analyses of global, cortical, and subcortical brain structures on clinical brain MRI T1w (n = 820) images from a retrospective, multi-center study (REMEMBER), icobrain dm's (v.4.4.0) ability to differentiate disease stages via ROC analysis was compared to FreeSurfer (v.6.0). Stepwise backward regression models were constructed to investigate if combined brain volumes can differentiate between AD stages.
resultsicobrain dm outperformed FreeSurfer in processing time (15-30 min versus 9-32 h), robustness (0 versus 67 failures), and diagnostic performance for whole brain, hippocampal volumes, and lateral ventricles between HC and ADD patients. Stepwise backward regression showed improved diagnostic accuracy for pairwise group differentiations, with highest performance obtained for distinguishing HC from ADD (AUC = 0.914; Specificity 83.0%; Sensitivity 86.3%).
conclusionAutomated volumetry has a diagnostic value for ADD diagnosis in routine clinical practice. Our findings indicate that combined brain volumes improve diagnostic accuracy, using real-world imaging data from a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.